Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 137

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 137
---
Description of Capital Stock—Warrants—Class B Warrants;” |

| • |     | 1,528,632 shares of our common stock issuable to Maxim Partners LLC upon the exercise of common stock warrants                                                                    
 outstanding as of June 30, 2025, with an exercise price of $0.01 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—Maxim Warrants;” |

| • |     | 71,761 shares of our common stock issuable upon the exercise of Series B-1 common stock warrants outstanding as                                                         
 of June 30, 2025, with an exercise price of $0.01 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—Series B-1 Warrants;” |

| • |     | 98,456 shares of our common stock issuable upon the exercise of New Series B common stock warrants outstanding as                                                         
 of June 30, 2025, with an exercise price of $1.50 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—New Series B Warrants;” |

| • |     | shares of common stock reserved for future issuance under our 2025 Plan, which became                                                                                                                                                                     
 effective upon the execution and delivery of the underwriting agreement for this offering, as well as any future automatic annual increases in the number of shares of common stock reserved for issuance under our 2025 Plan, as more fully described in 
 the section titled “Executive Compensation—Equity Benefit Plans;” and                                                                                                                                                                                     |

| • |     | shares of common stock reserved for future issuance under our ESPP, which became                                                                                                                                                                         
 effective upon the execution and delivery of the underwriting agreement for this offering, as well as any future automatic annual increases in the number of shares of common stock reserved for future issuance under our ESPP, as more fully described 
 in the section titled “Executive Compensation—Equity Benefit Plans.”                                                                                                                                                                                     |

90

DILUTION If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. Our historical net tangible book value as of June 30, 2025 was $10.4 million, or $1.48 per share of common